The United States, AstraZeneca announced that its September 2 coronary intravascular ultrasound study (SATURN) - rosuvastatin, atorvastatin compared to the impact of the latest research results. This study focused on 40mg of rosuvastatin (rosuvastatin calcium, crestor) and 80mg of atorvastatin (atorvastatin) on atherosclerosis in high-risk patients affected.

   Based on the percentage of atheroma volume (PAV) changes in the primary efficacy measures in the baseline study results showed that: compared to atorvastatin, rosuvastatin significantly reduced, but not statistically significant. 
   Targeted based on coronary plaque volume (TAV) changes in the secondary baseline IVUS measurements showed that: compared to atorvastatin, rosuvastatin was statistically significantly reduced. The results can be seen in the rosuvastatin compared to previous studies and approval of products, good tolerability and efficacy.

   More data and analysis on November 15 will be submitted to the American Heart Association Scientific Sessions (AHA) survey of academic research on the public